Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)

被引：0
|
作者：
Sorli, C. [1 ]
Harashima, S. -I. [2 ]
Tsoukas, G. [3 ]
Unger, J. [4 ]
Karsbol, J. Derving [5 ]
Hansen, T. [5 ]
Bain, S. [6 ]
机构：
[1] Billings Clin, Res Ctr, Billings, MT USA
[2] Grad Sch Med, Kyoto, Japan
[3] Dept Med, Montreal, PQ, Canada
[4] Catalina Res Inst, Chino, CA USA
[5] Novo Nordisk AS, Soborg, Denmark
[6] Sch Med, Swansea, W Glam, Wales
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
765
引用
收藏
页码：S364 / S364
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)
    Harashima, Shin-ichi
    Sorli, Christopher
    Tsoukas, George
    Unger, Jeffrey
    Karsbol, Julie Derving
    Hansen, Thomas
    Bain, Stephen
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S121 - S121
  • [2] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    [J]. DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [3] Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Chang, Denise
    Aroda, Vanita R.
    [J]. DIABETES, 2016, 65 : A49 - A49
  • [4] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
    Tan, Xueying
    Cao, Xiaojing
    Zhou, Minzhi
    Zou, Ping
    Hu, Jingbo
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1083 - 1089
  • [5] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    Aroda, Vanita
    Bain, Stephen
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Bergan, Eirik Quamme
    Zacho, Jeppe
    Devries, J. Hans
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [6] Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials
    Warren, M.
    Chaykin, L.
    Trachtenbarg, D.
    Nayak, G.
    Wijayasinghe, N.
    Cariou, B.
    [J]. DIABETOLOGIA, 2017, 60 : S378 - S379
  • [7] Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN 5)
    Rodbard, H.
    Lingvay, I.
    Reed, J.
    de la Rosa, R.
    Rose, L.
    Sugimoto, D.
    Araki, E.
    Chus, P. -L.
    Wijayasingh, N.
    Norwood, P.
    [J]. DIABETOLOGIA, 2016, 59 : S364 - S365
  • [8] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, Andrew
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Annett, Miriam
    Aroda, Vanita
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [9] Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in subjects with Type 2 diabetes (SUSTAIN 5)
    Rodbard, H.
    Lingvay, I.
    Reed, J.
    de la Rosa, R.
    Rose, L.
    Sugimoto, D.
    Araki, E.
    Chu, P-L
    Wijayasingh, N.
    Norwood, P.
    Subramanian, G.
    [J]. DIABETIC MEDICINE, 2017, 34 : 145 - 146
  • [10] Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3)
    Ahmann, A.
    Capehom, M.
    Charpentier, G.
    Dotta, E.
    Henkel, E.
    Lingvay, I.
    Holst, A. Gaarsdal
    Annett, M.
    Aroda, V.
    [J]. DIABETOLOGIA, 2016, 59 : S76 - S76
12345